Compositions and methods for prolonging survival of platelets

Abstract

The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

1 - 26 . (canceled) 
     
     
         27 . An isolated platelet modified ex vivo to comprise a plurality of terminally galactosylated modified glycan molecules on the surface of the platelet, wherein the modified platelets have a longer survival following mammalian transplant relative to unmodified platelets. 
     
     
         28 . The modified platelet of  claim 27 , wherein the modified glycan molecules are moieties of GP1bα molecules. 
     
     
         29 - 34 . (canceled) 
     
     
         35 . A platelet composition comprising a plurality of modified platelets according to  claim 27 . 
     
     
         36 . The platelet composition of  claim 35 , further comprising a storage medium. 
     
     
         37 . The platelet composition of  claim 35 , further comprising a pharmaceutically acceptable carrier. 
     
     
         38 - 51 . (canceled) 
     
     
         52 . A method for mediating hemostasis in a mammal comprising administering a plurality of platelets according to  claim 27 . 
     
     
         53 - 63 . (canceled) 
     
     
         64 . A method for mediating hemostasis in a mammal comprising administering the platelet composition of  claim 35  to the mammal. 
     
     
         65 . A method for mediating hemostasis in a mammal comprising administering the platelet composition of  claim 36  to the mammal. 
     
     
         66 . A method for mediating hemostasis in a mammal comprising administering the platelet composition of  claim 37  to the mammal.